Pharmacological Models of Alzheimer's Disease
Ace Therapeutics pioneers validated preclinical platforms to accelerate Alzheimer's disease (AD) therapeutic development. Our pharmacological models replicate AD-specific pathologies—from cholinergic deficits to Aβ-induced synaptic toxicity—enabling precise evaluation of cognitive enhancers, anti-aggregation agents, and neuroinflammatory modulators.
Our pharmacological models are meticulously designed to replicate key aspects of Alzheimer's disease pathology, providing researchers with reliable tools to study disease mechanisms and evaluate therapeutic interventions. These models are validated through rigorous behavioral, molecular, and histological analyses to ensure translational relevance.
| Model | Key Pathological Features | Primary Applications |
| Scopolamine-Induced Amnesia | Cholinergic dysfunction, hippocampal memory deficits | AChE inhibitor screening, NOR test validation |
| Aβ Oligomer Synaptotoxicity | Synaptic loss (20-35%), calcium dysregulation | Anti-aggregation drug testing, dendritic spine rescue |
| Hybrid Cholinergic-Aβ Model | Dual LTP suppression (60-70%), microglial activation | Multi-target therapy evaluation |
To comprehensively assess therapeutic efficacy, we combine advanced behavioral testing with molecular and cellular profiling. This integrated approach ensures a holistic understanding of drug effects on cognitive function, synaptic integrity, and neuroinflammatory pathways.
Cognitive Testing Suite
Radial arm maze
Passive avoidance
T-maze alternation
Neuropathology Platform
Synaptophysin/PDS95 Western blot quantification
Microglial activation profiling (Iba1+/CD68+ cells)
Cytokine multiplex analysis
Calcium Imaging Services
GCaMP6f-based neuronal calcium tracking
Aβ-induced calcium overload quantification
Channel blocker efficacy testing
Our mechanism-driven screening platforms are tailored to evaluate therapeutics targeting specific AD pathways. By combining high-resolution molecular assays with behavioral phenotyping, we provide actionable insights into drug efficacy and mechanisms of action.
Targeted Screening Platforms
| Therapeutic Class | Screening Metrics | Validation Methods |
| Cholinergic modulators | NOR test improvement ≥40% | AChE activity WB/ELISA |
| Aβ aggregation inhibitors | Oligomer reduction ≥60% (SEC-HPLC) | Synaptophysin IHC recovery |
| Microglial repolarization agents | CD206+/CD86+ ratio normalization | Phagocytosis assay |
Customizable Model Systems
| Specialized Model | Genetic/Pharmacological Features | Research Applications |
| APOE4-specific neuroinflammation | APOE ε4 knock-in + LPS challenge | APOE4-immune crosstalk studies |
| Inducible tauopathy | Tet-On hTauP301L expression | Temporal tau pathology analysis |
| Histaminergic-cholinergic dual model | H1R antagonist + scopolamine co-administration | Neurotransmitter interaction mapping |
Ace Therapeutics stands at the forefront of preclinical Alzheimer's disease research, providing cutting-edge pharmacological models and behavioral assays. Our comprehensive suite of services allows you to
Contact us to leverage
What is the scopolamine-induced amnesia model used for?
The scopolamine-induced amnesia model is primarily used to investigate memory impairments and the effects of cholinergic dysfunction, mimicking cognitive deficits seen in Alzheimer's disease.
How does the Aβ oligomer-induced model contribute to Alzheimer's research?
This model helps researchers understand the neurotoxic effects of amyloid-beta oligomers, including synaptic toxicity, neuroinflammation, and neuronal dysfunction, all of which are key factors in Alzheimer's disease progression.
What types of behavioral assays are used in Alzheimer's disease models?
We use a variety of behavioral assays, such as the novel object recognition (NOR) test, the Morris water maze, and fear conditioning, to assess memory and learning impairments in Alzheimer's models.
Can your models be used to test new Alzheimer's drugs?
Yes, our preclinical models are ideal for screening potential Alzheimer's drug candidates, evaluating their effectiveness in reversing memory deficits and neurodegenerative changes.
What therapeutic interventions can be tested in your Alzheimer's models?
Our models are used to test Aβ immunotherapy, tau-targeting drugs, anti-inflammatory agents, and cognitive enhancers, helping to identify potential treatments for Alzheimer's disease.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.